|
| 
WUXI APPTEC(2359)
Analysis：
It is Asia`s largest pharmaceutical R&D service platform based on 2017 revenue, accounting for 1.1% of the global pharmaceutical R&D outsourcing service market. The market share is 8.3% in China. Focusing on the discovery, development and manufacturing of small molecule drugs. It also provides research and development and manufacturing services for cell and gene therapies, accounting for 8.1% and 18.2% of the global and US cell and gene therapy CMO/CDMO market share, respectively. It ranked fourth and second respectively. In 2018, revenue increased by 23.8% year-on-year to RMB 9.613 billion (the same below), and net profit increased by 84.22% year-on-year to RMB 2.26 billion. The global pharmaceutical market grew at a CAGR of 4.9% from 2013 to 3017 and is expected to grow at a CAGR of 5.7% by 2022. China is the second largest pharmaceutical market in the world. It is expected that the policy will continue to encourage the development of innovative patented drugs in the next five years. It is expected that the generic and patented drugs will grow at a CAGR of 8% by 2022. The cell and gene therapy CMO/CDMO grew at a CAGR of 23.2% from 2013 to 2017 and is expected to grow at a CAGR of 24.2% by 2022.
Strategy：
Buy-in Price: $73.65, Target Price: $80.00, Cut Loss Price: $65.00
|
|
| Stock Code |
H share
Price |
A share
Price |
H share
discount |
| | | |
|
Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.
If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.
版權所有， 翻印必究。
Copyright(C) 2019 Phillip Securities (HK) Ltd. All Rights Reserved.
|
